Creisson C, Baulac L, Lenfant B
Postgrad Med J. 1986;62 Suppl 1:139-41.
Fifty-six elderly patients (mean age 72.1 +/- 4.1 years; mean creatinine 111.0 +/- 9.8 mumol/l were randomly assigned to either captopril (C) hydrochlorothiazide (HCT) fixed combination once daily (o.d.) (n = 29) or placebo (n = 27). Previous medication was stopped and following a run-in period of 2 weeks on placebo, the initial dosage was C (25 mg)/HCT (12.5 mg) o.d.; after 6 weeks it was increased to C (50 mg)/HCT (25 mg) o.d. for all the treated subjects; these doses were maintained for an additional 6 weeks. Blood pressure, heart rate, body weight and side effects were assessed every 2 weeks. After the run-in period as well as after the two treatment periods, routine biochemical examinations were carried out on all patients. Twenty to 24 hours after the last intake both C 25/HCT 12.5 o.d. and C 50/HCT 25 o.d. had significantly lowered blood pressure compared with placebo (P less than 0.001). The percentages of normalized patients (supine diastolic less than or equal to 90 mm Hg) were 3.7% (placebo), 72.4% (C25/HCT 12.5) after 6 weeks and 7.7% (placebo) and 96.6% (C 50/HCT 25) after 12 weeks. No important side effect was reported on captopril/hydrochlorothiazide combination. Haematological and biochemical changes were within the normal range in both groups. We conclude that a once daily captopril/hydrochlorothiazide combination is effective and safe in elderly patients with mild to moderate hypertension.
56例老年患者(平均年龄72.1±4.1岁;平均肌酐111.0±9.8μmol/L)被随机分为两组,一组每日一次服用卡托普利(C)/氢氯噻嗪(HCT)固定复方制剂(n = 29),另一组服用安慰剂(n = 27)。停用之前的药物,在服用2周安慰剂的导入期后,初始剂量为每日一次服用C(25mg)/HCT(12.5mg);6周后,所有治疗对象的剂量增加至每日一次服用C(50mg)/HCT(25mg);这些剂量再维持6周。每2周评估血压、心率、体重和副作用。在导入期以及两个治疗期结束后,对所有患者进行常规生化检查。在最后一次服药后20至24小时,与安慰剂相比,每日一次服用C 25/HCT 12.5和每日一次服用C 50/HCT 25均显著降低了血压(P<0.001)。血压正常化患者(仰卧位舒张压≤90mmHg)的百分比在6周时分别为3.7%(安慰剂组)、72.4%(C25/HCT 12.5组),在12周时分别为7.7%(安慰剂组)和96.6%(C 50/HCT 25组)。未报告卡托普利/氢氯噻嗪复方制剂有重要的副作用。两组的血液学和生化变化均在正常范围内。我们得出结论,每日一次服用卡托普利/氢氯噻嗪复方制剂对轻度至中度高血压老年患者有效且安全。